Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
| Autor: | Oleguer Parés-Badell, Ricardo Zules-Oña, Lluís Armadans, Laia Pinós, Blanca Borrás-Bermejo, Susana Otero, José Ángel Rodrigo-Pendás, Martí Vivet-Escalé, Yolima Cossio-Gil, Antònia Agustí, Cristina Aguilera, Magda Campins, Xavier Martínez-Gómez |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Parés-Badell O, Zules-Oña R, Pinós L, Vivet-Escalé M] Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca d’Epidemiologia i Salut Pública, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Armadans L, Borrás-Bermejo B, Otero S, Rodrigo-Pendás JÁ, Martínez-Gómez X] Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca d’Epidemiologia i Salut Pública, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat Docent, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Cossio-Gil Y] Unitat de Suport a la Decisió, Direcció de Sistemes d’Informació, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Gestió del Sistema Sanitari, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Agustí A] Servei de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Aguilera C] Servei de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Campins M] Grup de Recerca d’Epidemiologia i Salut Pública, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
SARS-CoV-2 COVID-19-vaccination booster dose mRNA vaccines adverse reactions health care workers Immunology Persons::Occupational Groups::Health Personnel [NAMED GROUPS] Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Personal sanitari Infectious Diseases Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy Active::Vaccination [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Drug Discovery Other subheadings::Other subheadings::/adverse effects [Other subheadings] virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] Pharmacology (medical) Vacunes - Efectes secundaris COVID-19 (Malaltia) - Vacunació personas::grupos profesionales::personal sanitario [DENOMINACIONES DE GRUPOS] |
| Zdroj: | Vaccines; Volume 10; Issue 8; Pages: 1217 Scientia |
| ISSN: | 2076-393X |
| DOI: | 10.3390/vaccines10081217 |
| Popis: | COVID-19-vaccination; Adverse reactions; Booster dose Vacunación de COVID-19; Reacciones adversas; Dosis de refuerzo Vacunació de COVID-19; Reaccions adverses; Dosi de reforç The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88.5%) was similar to the mRNA-1273 primary doses (85.8%), and higher than the BNT162b2 primary doses (71.1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88.0% vs. 90.2%, p = 0.3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1.45; 95% CI: 1.00–2.07; p = 0.045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|